Pfizer, Alex Therapeutics staff up on DTx effort initially targeted on nicotine cessation


Share post:

Pharma big Pfizer is setting its sights on the digital therapeutics area, inking a brand new strategic industrial partnership with Swedish startup Alex Therapeutics. 

The joint effort will faucet into Alex Therapeutics AI-based platform that integrates each cognitive behavioral remedy (CBT) and Acceptance and Dedication Remedy (ACT) with AI as a way to personalize care. Initially the pair will give attention to creating digital therapeutics for nicotine habit therapy and can begin its efforts within the German market. 

“In our efforts to provide sufferers entry to new, modern types of remedy, it’s our goal to totally profit from the chances of digitization. Alex Therapeutics is a really promising firm resulting from its method of mixing the most recent psychological findings on coping with dangerous conduct with the chances of synthetic intelligence,” mentioned Aylin Tüzel, nation supervisor for Pfizer Germany, explaining the selection of cooperation companion, in a press release.


The World Well being Group stories that tobacco kills greater than eight million people annually. Right this moment a number of digital well being corporations, together with Stop Genius, Carrot and CureApp SC have created digital instruments designed to assist with smoking cessation. 

Pfizer additionally has a historical past of working within the smoking cessation area. It beforehand launched a drug known as Chantix designed to assist sufferers give up smoking. Nevertheless, in September the corporate issued a voluntary nationwide recall of Chantix within the U.S. because of the degree of the nitrosamine N-nitroso-varenicline.


Pfizer has been within the digital therapeutic area for a while. In June 2020, the corporate introduced a partnership with Sidekick Well being price roughly $8 million as a way to launch a digital therapeutic platform. 

The corporate has additionally proven an curiosity in incorporating extra digital parts into analysis. Pfizer beforehand teamed up with the Digital Drugs Society (DiMe) and different life science corporations on a digital endpoint initiative targeted on atopic dermatitis. 

Many different massive life science corporations have explored the digital area. In Might, Novartis teamed up with medical AI firm Ada Well being on a brand new analysis for sufferers with immunological ailments and uncommon circumstances. Novartis has additionally labored with digital therapeutics firm Pear up to now, nevertheless, the pair break up methods in late 2019 on their high-profile collaboration round substance-abuse restoration therapeutics reSET and reSET-O. Novartis Institutes for BioMedical Analysis (NIBR) remains to be working with the corporate on its schizophrenia and a number of sclerosis analysis. 

Moreover, Sanofi has labored with digital therapeutic Happify Well being on treating a number of sclerosis signs since 2019. 


Supply hyperlink


Please enter your comment!
Please enter your name here


Related articles